COVID-19

Immunotherapy use is associated with a higher risk for hospitalization and severe coronavirus disease 2019 infection in patients with cancer and the novel respiratory virus.

Toni K. Choueiri, MD, discusses the impact the coronavirus disease 2019 pandemic has had on diagnosing and treating patients with renal cell carcinoma.

Steven Lee Chang, MD, MS, discusses the impact of the COVID-19 pandemic on surgical practices, alternative options to surgery, and potential lessons to be learned from the pandemic.

Telehealth is likely to stay in the oncology realm, even after the novel coronavirus 2019 pandemic passes.

Outbreaks of coronavirus disease 2019 are on the rise in Latin America, with more than 4 million confirmed cases. In response to this health crisis, elective medical procedures, including cancer screening and care, as well as treatment for conditions beyond the virus, have been held.

Patients in New York City with cancer who are then diagnosed with novel coronavirus 2019 (COVID-19) are marked by substantial hospitalization rates and severe outcomes.

Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.

The coronavirus disease 2019 has disrupted the global delivery of coordinated cancer care, resulting in declines in routine screening and referrals that could lead to thousands of excess deaths due to delayed diagnoses, experts warn.

The coronavirus disease 2019 pandemic has raised the public profile of experts in infectious disease, epidemiology, and public health.

An Emory University-led phase 2 study will evaluate whether the the PI3K-gamma/delta inhibitor duvelisib is effective at reducing lung inflammation in patients with severe novel coronavirus 2019, thereby decreasing incidences of mechanical ventilation and death in these patients.

Following a recent update from the Centers for Disease Control and Prevention, cancer has been added to the list of underlying medical conditions that may result in a more severe case of novel coronavirus 2019 should exposure to the virus occur.

The mortality rate with COVID-19 appears to be higher in patients with cancer—especially those with lung cancer—compared with the general population, and several factors associated with mortality are beginning to emerge.

Treatment with tocilizumab does not appear to inhibit the induction of anti-SARS-CoV-2 antibodies in patients with severe coronavirus disease 2019.

The situation with the coronavirus-19 pandemic continues to rapidly evolve, but one thing is clear: this is much more than just the common cold.

Treatment with immune checkpoint inhibitors did not increase the risk of mortality in patients with COVID-19 and cancer.

The National Cancer Institute has awarded the Sidney Kimmel Cancer Center – Jefferson Health a supplemental grant to study the role of telehealth in delivering cancer care during the COVID-19 pandemic.

Christine Sam, MD, discusses strategies to prevent the spread of COVID-19 in geriatric patients with cancer and shared advice on how to overcome unique challenges faced in the care of this population.

Treatment with the BTK inhibitor acalabrutinib resulted in decreased inflammation and improve outcomes in patients with severe coronavirus disease 2019.

Only a small percentage of patients with kidney cancer who are considered to be particularly vulnerable to COVID-19 have actually been tested for infection.

One of the major mysteries in treating patients with COVID-19 is the frequent development of blood clots that can subsequently damage their organs and sometimes be fatal.

Research efforts have revealed a potential weapon to add to the treatment arsenal against COVID-19, a drug that has historically played a crucial role in oncology treatment: the inexpensive, and widely accessible, corticosteroid dexamethasone.

Muhammad Bilal Abid, MD, MRCP, discusses the current coronavirus disease 2019 pandemic and its clinical impact on patients with cancer.

Following the arrival of the coronavirus disease 2019 pandemic, St. Jude Children's Research Hospital launched the first Global COVID-19 Observatory and Resource Center for Childhood Cancer.

The downstream effects of the coronavirus disease 2019 on patients with cancer have become apparent over the past few months, and the onus is on the field to provide clinical guidance on best practices in the absence of definitive data.

The FDA is presently spearheading several initiatives in light of COVID-19 aimed at refining the role of RWD in cancer care to guide clinical trial development, procure answers to pressing clinical questions, and support regulatory decisions for in vitro diagnostics.

Eric Brown, MD, FACS, discusses how breast oncologists and surgeons have adapted to overcome the challenges presented by COVID-19 and continue to deliver the best care to patients as the United States begins to re-open.

Results from a survey of patients in the United Kingdom showed patients with sickle cell disease diagnosed with COVID-19 and who had mild symptoms were more likely to die or require mechanical ventilation than those with more severe symptoms of COVID-19.

Andrew M. Evens, DO, MSc, discusses the telemedicine initiatives that have been taken at RCINJ—even before the COVID-19 outbreak—as well as proper telemedicine etiquette and best practices for oncologists getting a handle on the new approach in clinical practice.

This Onclive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC. Join us Thursday, June 23, 2020 at 8 PM EST.

Rana R. McKay, MD, discusses adapting treatment for patients with cancer during the coronavirus disease 2019 pandemic.